Keyword: PureTech Ventures
A PureTech startup is developing an immune-responsive hydrogel that releases a corticosteroid into arthritic joints based on their level of inflammation.
The round equips Gelesis to get its manufacturing and commercial arms ready for launch should regulators look favorably on its mixed late-phase data.
Four biotechs spanning a diverse set of therapy targets are seeking out nearly $400 million in a series of IPOs announced just before the New Year.
Success against the primary endpoint in the pivotal trial sets Akili up to file for FDA approval of the digital medicine.
PureTech affiliate Vedanta Biosciences announced a partnership to create immune-boosting cancer therapies that capitalize on the gut microbiome.
In this week's EuroBiotech Report, British biotech faces up to Brexit, Novartis offloads phase 2 assets, EMA plan criticized and more.
Novartis has offloaded two midphase mTORC1 inhibitors to PureTech Health in return for an equity stake and a source of future milestones and royalties.
Celgene president and COO Jackie Fouse makes a surprising departure, FDA's personalized medicine leader Elizabeth Mansfield joined Grail, former GSK neurosciences head Atul Pande came on board with PureTech, and Zomedica tapped industry veteran Robert DiMarzo as EVP.
Former Moderna and Millennium exec Joseph Bolen has returned as the CSO of PureTech Health.
Just one day after launching Vor BioPharma, Boston’s VC-cum-research biotech has launched another new preclinical company, this time focused on inflammatory disorders.